Compare GRI & SOBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRI | SOBR |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.3M |
| IPO Year | 2020 | 2008 |
| Metric | GRI | SOBR |
|---|---|---|
| Price | $2.37 | $0.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $160.00 | N/A |
| AVG Volume (30 Days) | 31.4K | ★ 147.5K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.19 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $212,736.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.18 | $0.48 |
| 52 Week High | $6.70 | $5.80 |
| Indicator | GRI | SOBR |
|---|---|---|
| Relative Strength Index (RSI) | 46.45 | 34.65 |
| Support Level | $2.16 | N/A |
| Resistance Level | $2.66 | $1.03 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 30.71 | 16.32 |
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.